EZH2 and melanoma: This notion is supported by recent data of Zingg et al. [23] demonstrating that intratumoral T-cell accumulation—among other factors—can result in increased EZH2 expression in melanoma cells, which in return leads to a loss of immunogenicity and antigen presentation in EZH2 overexpressing tumor cells.